Devyser Diagnostics AB (publ) (DVYSR.ST)

SEK 117.0

(0.0%)

EBITDA Summary of Devyser Diagnostics AB (publ)

  • Devyser Diagnostics AB (publ)'s latest annual EBITDA in 2023 was -43.8 Million SEK , up 4.28% from previous year.
  • Devyser Diagnostics AB (publ)'s latest quarterly EBITDA in 2024 Q1 was -10.6 Million SEK , up 63.85% from previous quarter.
  • Devyser Diagnostics AB (publ) reported an annual EBITDA of -46.02 Million SEK in 2022, down -163.28% from previous year.
  • Devyser Diagnostics AB (publ) reported an annual EBITDA of -18.05 Million SEK in 2021, down -364.2% from previous year.
  • Devyser Diagnostics AB (publ) reported a quarterly EBITDA of -22.8 Million SEK for 2024 Q3, up 3.11% from previous quarter.
  • Devyser Diagnostics AB (publ) reported a quarterly EBITDA of -10.6 Million SEK for 2024 Q1, up 63.85% from previous quarter.

Annual EBITDA Chart of Devyser Diagnostics AB (publ) (2023 - 2018)

Historical Annual EBITDA of Devyser Diagnostics AB (publ) (2023 - 2018)

Year EBITDA EBITDA Growth
2023 -43.8 Million SEK 4.28%
2022 -46.02 Million SEK -163.28%
2021 -18.05 Million SEK -364.2%
2020 -6.96 Million SEK -136.4%
2019 13.26 Million SEK 584.24%
2018 1.6 Million SEK 0.0%

Peer EBITDA Comparison of Devyser Diagnostics AB (publ)

Name EBITDA EBITDA Difference
AroCell AB (publ) -13.75 Million SEK -218.337%
Immunovia AB (publ) -166.55 Million SEK 73.703%
Prostatype Genomics AB (publ) -38.02 Million SEK -15.203%
SenzaGen AB -13.53 Million SEK -223.582%
Spermosens AB -10.7 Million SEK -309.193%